Last day of trading with Allarity Therapeutics A/S BTU
June 24, 2021 10:05 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (24 June 2021) – Allarity Therapeutics A/S (“Allarity”) today announced that the recently completed Rights Issue, announced on 10 June 2021, has now been registered...
Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
June 14, 2021 07:00 ET
|
Allarity Therapeutics A/S
Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancersAllarity is preparing to file a first U.S. new drug application (NDA) for the approval...
Allarity Therapeutics Completes Oversubscribed Rights Issue
June 10, 2021 18:01 ET
|
Allarity Therapeutics A/S
– Allarity raises SEK 102.8 million before issue costs to further finance the development of three high-priority pipeline programs – The Rights Issue of Units was subscribed for approximately 106...
Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic
June 09, 2021 05:08 ET
|
Allarity Therapeutics A/S
– Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib,...
Allarity Therapeutics Publishes Interim Report for the Period January – March 2021
May 28, 2021 07:45 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (28 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – March 2021. The...
Allarity Therapeutics Publishes Prospectus Supplement
May 27, 2021 09:21 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (27 May 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the Company’s Board of Directors has approved a Supplement to the...
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
May 21, 2021 01:00 ET
|
Allarity Therapeutics A/S
US $20 million investment by 3i Fund is conditioned upon completion of the recapitalization into a newly organized Delaware holding company (Allarity Therapeutics, Inc.) and a listing of its common...
Allarity Therapeutics to Conduct a Rights Issue of New Shares, and Publishes Prospectus regarding the Rights Issue
May 19, 2021 02:30 ET
|
Allarity Therapeutics A/S
- Proceeds will finance further development of three high-priority programs - More than SEK 100 million covered by subscription undertakings and guarantee commitments Press release Hørsholm,...
Allarity Therapeutics Updates Preliminary Timetable for Planned Rights Issue
May 05, 2021 17:11 ET
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (5 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced an update of the preliminary timetable for the planned Rights Issue announced on...
Allarity Therapeutics To Present a Dovitinib-DRP® e-Poster at the European Association for Cancer Research (EACR) 2021 Virtual Congress
April 29, 2021 10:31 ET
|
Allarity Therapeutics A/S
- Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib - Poster provides new details of the DRP® companion diagnostic for dovitinib,...